Here's your product review and approval news for the week in brief: The US Food and Drug Administration has now cleared a dozen treatments under its Real-Time Oncology Review (RTOR) pilot program with approvals last week for Merck & Co. Inc. and Eisai Co. Ltd.'s Keytruda (pembrolizumab)/Lenvima (lenvatinib) combination and Janssen Pharmaceutical Cos.'s Erleada (apalutamide).
Another notable approval went to Novo Nordisk AS's oral semaglutide product Rybelsus for the treatment of type 2 diabetes,...





